Teva, Active Biotech halt higher doses of oral MS drug in trials

JERUSALEM (Reuters) - Teva Pharmaceutical Industries and Active Biotech will discontinue higher doses of their oral drug in development for multiple sclerosis in two trials, citing the occurrence of non-fatal cardiovascular events in eight patients.

http://ift.tt/xePdMM

from Reuters: Health News
via animenewspro